Estimated according to the population size and structure, there are about 330 million hypertensive patients in China, which means that one in every three adults suffers from hypertension. Chinese hypertensive patients in China account for about one-third of the global total.The Market Size of Metoprolol in China was about CNY 492 Million in 2017
The incidence of hypertension in China rose from 5.1% in 1959 to 37.2% in 2017 by 32.1%. With so many hypertensive patients, China’s antihypertensive drug market is growing steadily.
There are various antihypertensive drugs in China, which leads to fierce competition. As first-line antihypertensive drugs in China, ß-blockers represented by Metoprolol, Bisoprolol, Perindopril and benazepril have a stable market share. Metoprolol is a selective ß1 receptor blocker that treats cardiovascular diseases, especially hypertension, angina and tachycardia.
The Metoprolol Tartrate preparations approved to be marketed in China include tablets, capsules, sustained-release tablets, controlled-release tablets and injections. AstraZeneca's proprietary drug is sold in the trade name of Betaloc. In addition, generic Metoprolol produced by over 10 manufacturers are also sold in China.
According to the publisher's market research, the market size of Metoprolol in China was about CNY 492 million in 2017, of which AstraZeneca accounted for more than 90%. The top Chinese companies included Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., Shanghai Sine Promod Pharmaceutical Co., Ltd. and Zhuhai Tongyuan Pharmaceutical Co., Ltd.
As the number of hypertensive patients is growing with the rapidly aging population, and generic ß-blockers are popularized, it is expected that Metoprolol will still have some growth potential in China.
Topics Covered:
- Situation of hypertension in China
- Sales of Metoprolol in China
- Major Metoprolol manufacturers in China
- Competition on China's Metoprolol market
- Driving forces and opportunities for China's Metoprolol market
- Forecasts on China's Metoprolol market from 2018 to 2022
Table of Contents
Companies Mentioned
- AstraZeneca (Betaloc)
- Changzhou Siyao Pharmaceuticals Co., Ltd.
- Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Lijunning)
- Shanghai Sine Promod Pharmaceutical Co., Ltd.
- Zhuhai Tongyuan Pharmaceutical Co., Ltd.
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
